Aptocrom
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aptocrom distributes prescription and over-the-counter medicines, including topical treatments, digestive drugs, nutritional supplements, and antibiotics, to the healthcare market in South Korea.
It also leases its own real estate and equipment, and through a subsidiary provides specialist thermal-insulation systems for nuclear power plants. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company operates across three distinct segments: pharmaceuticals distribution, property rental, and insulation services.
Summary is AI-generated and may contain errors · figures from DART filings
Aptocrom's subsidiary Aprogen I&C Co., Ltd. focuses on nuclear-plant-specific insulation design, fabrication, and installation, a highly regulated niche within South Korea's energy infrastructure sector.
Aptocrom in five facts
What does Aptocrom do?
Aptocrom distributes prescription and over-the-counter medicines, including topical treatments, digestive drugs, nutritional supplements, and antibiotics, to the healthcare market in South Korea.
Where is Aptocrom listed and in which sector?
Aptocrom (Korean name: 앱토크롬) trades under KRX code 109960 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Trading & Distribution.
How large is Aptocrom?
Its market capitalisation was US$21.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Aptocrom's latest annual revenue and operating profit?
For fiscal year 2025, Aptocrom reported revenue of US$7.4M, an operating loss of US$1.7M and a net loss of US$4.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 40.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Material event report (rights offering)
Aptocrom updated the terms of a private placement (third-party allotment) to raise US$8.07M, about 42.5% of its market value.
Capital raise · Apr 29 · 2 versions - Trading suspension (share consolidation/split registration)M&A · Apr 28
- Early redemption of bonds with warrantsCapital raise · Apr 27
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Aptocrom reported consolidated results for FY2025: revenue of US$6.85M (−40.2% year on year), an operating loss of US$1.6M (from a profit a year earlier) and a net loss of US$2.47M.
Earnings · Feb 27 - Early redemption of bonds with warrantsCapital raise · Jan 26